MedTrace Logo

Seizure Activity in Alzheimer's Disease

NCT01554683 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-07-23

Study results available
· View outcomes & findings →

Summary

The main purpose of this research project is to study how seizure-like activity affects the blood flow in the brain of patients with Alzheimer's disease (AD). Changes in blood flow can change memory and thinking ability, as happens in Alzheimer's disease. The investigators are using a study drug called Levetiracetam, which helps control seizure-like activity to see if it can help change the abnormal blood flow in the brain that is seen in some people with Alzheimer's disease.

Conditions

Interventions

DRUG

Low/High/Placebo Dose Keppra (Levetiracetam)

Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)

Sponsors & Collaborators

Principal Investigators

  • Dan Press, M.D. · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2017-07-01
Completion
2017-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554683 on ClinicalTrials.gov